BR9508991A - Composto processo para preparação de um composto composição farmacêutica processo para o tratamento de hiperglicemia obesidade arteriosclerose hiperinsulinemia distúrbios gastrointestinais ou o tratamento de ulcerações gastrointestinais em um mamifero humano ou não-humano processo para aumentar o ganho de peso e/ou aperfeiçoar a eficiência da utilização de alimentação e/ou aumentar a curva da massa de corpo e/ou diminuir a taxa de mortalidade de nascimento e aumentar a taxa de sobrevivência pós-natal de animais de criação e formulação de prè-mistura veterinariamente aceitâvel - Google Patents
Composto processo para preparação de um composto composição farmacêutica processo para o tratamento de hiperglicemia obesidade arteriosclerose hiperinsulinemia distúrbios gastrointestinais ou o tratamento de ulcerações gastrointestinais em um mamifero humano ou não-humano processo para aumentar o ganho de peso e/ou aperfeiçoar a eficiência da utilização de alimentação e/ou aumentar a curva da massa de corpo e/ou diminuir a taxa de mortalidade de nascimento e aumentar a taxa de sobrevivência pós-natal de animais de criação e formulação de prè-mistura veterinariamente aceitâvelInfo
- Publication number
- BR9508991A BR9508991A BR9508991A BR9508991A BR9508991A BR 9508991 A BR9508991 A BR 9508991A BR 9508991 A BR9508991 A BR 9508991A BR 9508991 A BR9508991 A BR 9508991A BR 9508991 A BR9508991 A BR 9508991A
- Authority
- BR
- Brazil
- Prior art keywords
- increasing
- treatment
- compound
- human
- gastrointestinal
- Prior art date
Links
- 238000000034 method Methods 0.000 title 3
- 150000001875 compounds Chemical class 0.000 title 2
- 206010003210 Arteriosclerosis Diseases 0.000 title 1
- 208000018522 Gastrointestinal disease Diseases 0.000 title 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 title 1
- 241001465754 Metazoa Species 0.000 title 1
- 208000008589 Obesity Diseases 0.000 title 1
- 208000025865 Ulcer Diseases 0.000 title 1
- 208000011775 arteriosclerosis disease Diseases 0.000 title 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 title 1
- 230000003247 decreasing effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 230000002496 gastric effect Effects 0.000 title 1
- 201000001421 hyperglycemia Diseases 0.000 title 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 title 1
- 201000008980 hyperinsulinism Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000004083 survival effect Effects 0.000 title 1
- 230000036269 ulceration Effects 0.000 title 1
- 230000004584 weight gain Effects 0.000 title 1
- 235000019786 weight gain Nutrition 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/303—Cycloaliphatic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3223—Esters of cycloaliphatic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9415304A GB9415304D0 (en) | 1994-07-29 | 1994-07-29 | Novel compounds |
GB9423179A GB9423179D0 (en) | 1994-11-17 | 1994-11-17 | Novel compounds |
GBGB9510485.7A GB9510485D0 (en) | 1995-05-24 | 1995-05-24 | Novel compounds |
PCT/EP1995/003037 WO1996004233A1 (en) | 1994-07-29 | 1995-07-27 | Aryloxy and arylthiopropanolamine derivatives useful as beta 3-adrenoreceptor agonists and antagonists of the beta 1 and beta 2-adrenoreceptors and pharmaceutical composition thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9508991A true BR9508991A (pt) | 1997-10-21 |
Family
ID=27267307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9508991A BR9508991A (pt) | 1994-07-29 | 1995-07-27 | Composto processo para preparação de um composto composição farmacêutica processo para o tratamento de hiperglicemia obesidade arteriosclerose hiperinsulinemia distúrbios gastrointestinais ou o tratamento de ulcerações gastrointestinais em um mamifero humano ou não-humano processo para aumentar o ganho de peso e/ou aperfeiçoar a eficiência da utilização de alimentação e/ou aumentar a curva da massa de corpo e/ou diminuir a taxa de mortalidade de nascimento e aumentar a taxa de sobrevivência pós-natal de animais de criação e formulação de prè-mistura veterinariamente aceitâvel |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0772585A1 (hu) |
JP (1) | JPH10503507A (hu) |
CN (1) | CN1159797A (hu) |
AU (1) | AU3254695A (hu) |
BR (1) | BR9508991A (hu) |
CA (1) | CA2196193A1 (hu) |
CZ (1) | CZ25597A3 (hu) |
HU (1) | HUT76800A (hu) |
MX (1) | MX9700765A (hu) |
NO (1) | NO970372L (hu) |
PL (1) | PL318381A1 (hu) |
WO (1) | WO1996004233A1 (hu) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9605495D0 (en) * | 1996-03-15 | 1996-05-15 | Smithkline Beecham Plc | Novel compounds |
US5914339A (en) * | 1996-05-14 | 1999-06-22 | American Home Products Corporation | Substituted 1,3-benzodioxoles |
EP0827746B1 (en) | 1996-09-05 | 2002-04-03 | Eli Lilly And Company | Carbazole analogues as selective beta3 adrenergic agonists |
WO1998022480A1 (en) * | 1996-11-18 | 1998-05-28 | Smithkline Beecham Plc | Phosphorus containing aryloxy or arylthio propanolamine derivatives |
GB9703492D0 (en) * | 1997-02-20 | 1997-04-09 | Smithkline Beecham Plc | Novel compounds |
CO5011072A1 (es) | 1997-12-05 | 2001-02-28 | Lilly Co Eli | Etanolaminas pirazinil substituidas como agfonistas de los receptores |
DK0980375T3 (da) * | 1998-01-30 | 2006-03-13 | Boulder Scient Co | Syntese af silylerede og N-silylerede forbindelser |
EP1070046A1 (en) | 1998-04-06 | 2001-01-24 | Fujisawa Pharmaceutical Co., Ltd. | Propanolamine derivatives |
AUPP549998A0 (en) * | 1998-08-26 | 1998-09-17 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
US7098248B2 (en) | 2001-07-09 | 2006-08-29 | Research Development Foundation | Beta-adrenergic blockade reversal of catabolism after severe burn |
DE102008064003A1 (de) * | 2008-12-19 | 2010-06-24 | Clariant International Limited | Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung |
CN107266341B (zh) * | 2017-06-23 | 2020-01-07 | 华东师范大学 | 芳氧基取代丙-2-醇胺的衍生物作为β3肾上腺素能受体拮抗剂、制备方法和用途 |
CN112442167A (zh) * | 2019-08-28 | 2021-03-05 | 广东广山新材料股份有限公司 | 一种反应型阻燃剂及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1262729A (en) * | 1983-10-19 | 1989-11-07 | Leo Alig | Phenoxypropanolamines |
DE3866984D1 (en) * | 1987-07-21 | 1992-01-30 | Hoffmann La Roche | Phenoxypropanolamine. |
GB8801306D0 (en) * | 1988-01-21 | 1988-02-17 | Ici Plc | Chemical compounds |
GB9215844D0 (en) * | 1992-07-25 | 1992-09-09 | Smithkline Beecham Plc | Novel compounds |
-
1995
- 1995-07-27 CA CA002196193A patent/CA2196193A1/en not_active Abandoned
- 1995-07-27 EP EP95929029A patent/EP0772585A1/en not_active Withdrawn
- 1995-07-27 MX MX9700765A patent/MX9700765A/es unknown
- 1995-07-27 JP JP8506193A patent/JPH10503507A/ja active Pending
- 1995-07-27 BR BR9508991A patent/BR9508991A/pt not_active Application Discontinuation
- 1995-07-27 WO PCT/EP1995/003037 patent/WO1996004233A1/en not_active Application Discontinuation
- 1995-07-27 CN CN95195371A patent/CN1159797A/zh active Pending
- 1995-07-27 PL PL95318381A patent/PL318381A1/xx unknown
- 1995-07-27 AU AU32546/95A patent/AU3254695A/en not_active Abandoned
- 1995-07-27 HU HU9700262A patent/HUT76800A/hu unknown
- 1995-07-27 CZ CZ97255A patent/CZ25597A3/cs unknown
-
1997
- 1997-01-28 NO NO970372A patent/NO970372L/no unknown
Also Published As
Publication number | Publication date |
---|---|
WO1996004233A1 (en) | 1996-02-15 |
PL318381A1 (en) | 1997-06-09 |
JPH10503507A (ja) | 1998-03-31 |
NO970372D0 (no) | 1997-01-28 |
NO970372L (no) | 1997-03-18 |
CZ25597A3 (cs) | 1998-02-18 |
HUT76800A (en) | 1997-11-28 |
AU3254695A (en) | 1996-03-04 |
EP0772585A1 (en) | 1997-05-14 |
MX9700765A (es) | 1997-05-31 |
CN1159797A (zh) | 1997-09-17 |
CA2196193A1 (en) | 1996-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9508991A (pt) | Composto processo para preparação de um composto composição farmacêutica processo para o tratamento de hiperglicemia obesidade arteriosclerose hiperinsulinemia distúrbios gastrointestinais ou o tratamento de ulcerações gastrointestinais em um mamifero humano ou não-humano processo para aumentar o ganho de peso e/ou aperfeiçoar a eficiência da utilização de alimentação e/ou aumentar a curva da massa de corpo e/ou diminuir a taxa de mortalidade de nascimento e aumentar a taxa de sobrevivência pós-natal de animais de criação e formulação de prè-mistura veterinariamente aceitâvel | |
Vala et al. | Medicinal benefits of coconut oil | |
BR0009219A (pt) | Ração para animal de estimação para a manutenção da saúde das articulações e alìvio dos sintomas de artrite em animais de companhia | |
JP2006525243A5 (hu) | ||
MXPA03010612A (es) | Ligandos receptores de la hormona concentradora de melanina: analogos de 1-bencil-4-aril piperazina substiruidos. | |
Dhanalakshmi et al. | Protective effect of Triphala on cold stress-induced behavioral and biochemical abnormalities in rats | |
WO2006015279A8 (en) | Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders | |
BR112015020019B1 (pt) | forma de dosagem farmacêutica e seu uso | |
Pagan | Gastric ulcers in horses: a widespread but manageable disease | |
RU2009136424A (ru) | Композиция и способ лечения папилломавируса и саркоидов лошадей | |
Cronin | Nutraceutical of the next century? | |
Jimmy et al. | Aloe vera heals gastric ulcer in 7 days than omeprazole and cimetidine: prostaglandin | |
Mandal et al. | A study to evaluate efficacy of Tinospora cordifolia (Guduchi) as analgesic agent using albino wistar rats as an experimental animal model | |
Calhoun et al. | Interaction studies of tilomisole, aspirin, and naproxen in acute and chronic inflammation with assessment of gastrointestinal irritancy in the rat | |
Karkola et al. | Deaths caused by animals in Finland | |
CN212037821U (zh) | 一种畜牧兽医用灌药器 | |
Bath | Hexachlorophene toxicity in dogs | |
Canello et al. | Unraveling a commercial formula to relieve halitosis in dogs | |
Gould et al. | Indomethacin and 7, 12‐dimethylbenz (a) anthraceneinduced carcinogenesis in the hamster buccal pouch | |
RU2634347C1 (ru) | Лечебно-профилактическая зубная паста | |
Solanki et al. | Indigenous knowledge of veterinary medicines among tribals of West Nimar. | |
Henderson et al. | Maxillary dento-alveolar abscess in a spotted hyaena Crocuta crocuta | |
KR20240126455A (ko) | 통증 완화용 피부 외용제 조성물 | |
RU94042745A (ru) | Способ профилактики, нормализации и лечения нарушений и болезней обмена веществ у молодняка крупного рогатого скота | |
Bartels | Studies of local anaesthetics for velvet antler analgesia: a thesis presented in partial fulfilment of the requirements for the degree of Master of Science at Massey University |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EG | Technical examination (opinion): publication of technical examination (opinion) | ||
FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
FA8 | Dismissal: dismissal - article 36, par. 1 of industrial property law |